GENE ONLINE|News &
GRI Bio Secures UAE Patent Allowance for Type 2 NKT Cell Agonists Targeting Inflammatory Conditions
GRI Bio has received a Notice of Allowance for its patent application in the United Arab Emirates, covering novel Type 2 diverse NKT cell agonists designed for the treatment of inflammatory conditions. The development marks a significant step in the company’s intellectual property portfolio, specifically targeting advancements in therapies aimed at addressing inflammation-related diseases.
The patent application focuses on innovative compounds that act as agonists to Type 2 natural killer T (NKT) cells, which play a role in modulating immune responses. These compounds are intended to address various inflammatory conditions by leveraging their ability to influence immune system activity. The UAE patent allowance adds to GRI Bio’s growing list of global intellectual property protections and underscores its ongoing efforts to develop therapeutic solutions for complex medical challenges.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: April 8, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
FDA Grants Full Approval to Travere Therapeutics’ FILSPARI as First Medication for Treating FSGS
2026-04-13
High Income Securities Fund Announces Monthly Distribution Schedule for Second Quarter of 2026
2026-04-13
Walker & Dunlop Expands Affordable Housing Team with Addition of Jack Hodgkins and Stacie Nekus
2026-04-13
Aura Minerals Updates 2026 CAPEX Guidance to Include Era Dorada Project Construction Costs
2026-04-13
EVENT
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
